Pembrolizumab versus chemotherapy in recurrent, advanced urothelial cancer in Japanese patients: a subgroup analysis of the phase 3 KEYNOTE-045 trial

BACKGROUND: The open-label, randomized, active-controlled KEYNOTE-045 study (NCT02256436) showed that second-line pembrolizumab significantly improved overall survival (OS) of patients with advanced/metastatic urothelial cancer (UC) that progressed after first-line platinum-containing chemotherapy,...

Descripción completa

Detalles Bibliográficos
Autores principales: Nishiyama, Hiroyuki, Yamamoto, Yoshiaki, Sassa, Naoto, Nishimura, Kazuo, Fujimoto, Kiyohide, Fukasawa, Satoshi, Yokoyama, Minato, Enokida, Hideki, Takahashi, Kenichi, Tanaka, Yoshinobu, Imai, Kentaro, Shimamoto, Takashi, Perini, Rodolfo, Frenkl, Tara, Bajorin, Dean, Bellmunt, Joaquim
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Singapore 2019
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6946746/
https://www.ncbi.nlm.nih.gov/pubmed/31729625
http://dx.doi.org/10.1007/s10147-019-01545-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6946746/
https://www.ncbi.nlm.nih.gov/pubmed/31729625
http://dx.doi.org/10.1007/s10147-019-01545-4

Ejemplares similares